Abstract
Small cell lung cancer (SCLC) is a heterogeneous malignancy with dismal prognosis. As molecular subtyping of SCLC with distinct genomic and transcriptional profiles have been identified, the treatment of SCLC has entered the era of precision medicine. However, few studies have conducted on the heterogeneity among SCLC patients from the perspective of metabolism. Therefore, in the present study, we aimed to identify SCLC classifications in terms of untargeted metabolomics and lipidomics. We also compared the survival and the immunotherapy responses among these subgroups.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
